Peer-reviewedCC BY-NC-NDTranslational cancer research
Telmisartan enhances anti-PD-1 efficacy in MSS colorectal cancer via modulation of PD-L1 and STAT3 signaling
- 1Department of Oncology , Fuzhou University Affiliated Provincial Hospital , Fuzhou , ;
- 2College of Biological Science and Engineering , Fuzhou University , Fuzhou , ;
- 3Department of Cardiovascular Medicine , Fuzhou University Affiliated Provincial Hospital , Fuzhou ,
Related
- Selinexor enhances temozolomide efficacy in glioblastoma through modulation of multiple resistance-associated mechanisms
- RAD51D deficiency enhances IFN-JAK-STAT signaling to upregulate PD-L1 and increase sensitivity to PD-L1 blockade in colorectal cancer
- Antibody-drug conjugate combination therapy targeting LGR5 and MET with different payloads enhances efficacy in preclinical colorectal cancer models
- Epigenetic modulation of NKG2D ligands enhances NKG2D-CAR T cell efficacy in neuroblastoma.
- PGG Enhances Olaparib Efficacy via cGAS-STING Signaling and Sensitizes Triple-Negative Breast Cancer to PD- L1 Blockade
BibTeX
@article{lin2026telmisartan,
title = {{Telmisartan enhances anti-PD-1 efficacy in MSS colorectal cancer via modulation of PD-L1 and STAT3 signaling}},
author = {Xin Lin and Jingying Li and Wei Lin},
journal = {Translational cancer research},
year = {2026},
month = aug,
url = {https://europepmc.org/article/PMC/PMC13657849},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Telmisartan enhances anti-PD-1 efficacy in MSS colorectal cancer via modulation of PD-L1 and STAT3 signaling
AU - Xin Lin
AU - Jingying Li
AU - Wei Lin
PY - 2026
DA - 2026/08/14
JO - Translational cancer research
UR - https://europepmc.org/article/PMC/PMC13657849
SN - 2218-676X
ER -